Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vimian Group ABVIMGF 70 Debt-to-Equity is 0.38 as of Jun. 2026, which is at its 10-year median of 0.38. GuruFocus rates VIMGF with a GF Score™ of 70/100 and a GF Value™ of $2.87. The stock has 4 warning signs investors should review. Among 182 Medical Diagnostics & Research companies, Vimian Group AB ranks worse than 53.85% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Vimian Group AB's Debt-to-Equity or its related term are showing as below:
VIMGF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.27 Med: 0.38 Max: 0.85
Current: 0.38
During the past 9 years, the highest Debt-to-Equity Ratio of Vimian Group AB was 0.85. The lowest was 0.27. And the median was 0.38.
VIMGF's Debt-to-Equity is ranked worse than 53.85% of 182
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.325
vs VIMGF: 0.38
Vimian Group AB (OTCPK:VIMGF) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Vimian Group AB Debt-to-Equity Related Terms
Vimian Group AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Vimian Group AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VIMGF vs TMO, DHR, IDXX: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Vimian Group AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vimian Group AB Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vimian Group AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Vimian Group AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vimian Group AB (VIMGF) has a Debt-to-Equity of 0.38 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Vimian Group AB and its competitors. This is near median its historical median of 0.38. Over the past decade, Vimian Group AB's Debt-to-Equity has ranged from 0.27 to 0.85. According to the industry distribution chart, Vimian Group AB ranks #98 out of 182 companies in the Medical Diagnostics & Research industry, placing it in the top 53.8%.
Is Vimian Group AB's Debt-to-Equity too high?
Vimian Group AB's current Debt-to-Equity of 0.38 is near median its 10-year median of 0.38. Over the past 10 years, this metric has ranged from a low of 0.27 to a high of 0.85. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.33. Vimian Group AB's value of 0.38 is 16.9% above this industry median. Based on the distribution chart, Vimian Group AB ranks #98 out of 182 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Vimian Group AB has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does Vimian Group AB's Debt-to-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vimian Group AB ranks #98 out of 182 companies for Debt-to-Equity. This places Vimian Group AB in the lower half of its industry. The industry median Debt-to-Equity is 0.33. Vimian Group AB's value of 0.38 is 16.9% above this benchmark. Historically, Vimian Group AB's own Debt-to-Equity has ranged from 0.27 to 0.85 over the past decade. While the company's 10-year median is 0.38 vs. the industry median of 0.33, Vimian Group AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.33, based on 182 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vimian Group AB's current Debt-to-Equity of 0.38 is 16.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Vimian Group AB and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vimian Group AB's current Debt-to-Equity is 0.38, which is near median its own 10-year median of 0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimian Group AB stock overvalued right now?
Vimian Group AB (VIMGF) has a current Debt-to-Equity of 0.38. The stock's GF Value™ is $2.87, compared to a current price of $2.77 — trading 3.5% below its estimated fair value. The current Debt-to-Equity is 0.38, which is near median its 10-year median of 0.38 and 16.9% above the Medical Diagnostics & Research industry median of 0.33. Vimian Group AB's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Vimian Group AB (VIMGF), the current Debt-to-Equity is 0.38 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vimian Group AB (VIMGF) Overvalued in 2026?
Based on GuruFocus' analysis, Vimian Group AB stock appears to be undervalued.
The current stock price of $2.77 is trading 3.5% below its estimated GF Value™ of $2.87.
Key valuation signals for VIMGF:
Debt-to-Equity: 0.38 (near median its 10-year median of 0.38)
GF Value™: $2.87 vs. price of $2.77 (3.5% below fair value)
Industry Position: 16.9% above the Medical Diagnostics & Research median (#98 of 182)
No single metric tells the full story. See the VIMGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vimian Group AB specializes in the areas of animal health, such as specialty pharma, diagnostics, medtech, and veterinary services. It offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals, with a position within allergy, dermatology, otology, and specialized nutrition. Its geographical segments include Europe, North America, and the Rest of the world.
70GF Score
Get the complete analysis for VIMGF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VIMGF has been successfully added to your 
